68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer

Clin Nucl Med. 2016 May;41(5):423-5. doi: 10.1097/RLU.0000000000001158.


Prostate cancer was diagnosed in a 71-year-old man with an elevated prostate-specific antigen. The CT of the abdomen showed multiple para-aortal lymph nodes, and thus, a Ga anti-prostate-specific membrane antigen (PSMA-11) PET/CT was initiated, which showed, aside from the prostate cancer and multiple iliacal and para-aortal lymph node metastases, an increased tracer uptake in a lymph node left cervical. According to this advanced disease, a palliative therapy with GnRH agonist was initiated. A second PSMA-11 PET/CT was performed 4 months later, which showed a very good response; thus, additional radiation of the pelvis and the draining lymphatic system was performed.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Antigens, Surface / metabolism*
  • Biomarkers, Tumor / metabolism*
  • Gallium Radioisotopes
  • Glutamate Carboxypeptidase II / metabolism*
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Male
  • Positron-Emission Tomography / methods
  • Prostate-Specific Antigen / metabolism*
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / drug therapy
  • Tomography, X-Ray Computed / methods


  • Androgen Antagonists
  • Antigens, Surface
  • Biomarkers, Tumor
  • Gallium Radioisotopes
  • Gonadotropin-Releasing Hormone
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
  • Prostate-Specific Antigen